Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2005

View Archived Issues

Levetiracetam improves chorea symptoms in patients with Huntington's disease

Ralfinamide induces analgesic effects in patients with neuropathic pain

VasoGenix and QLT to develop new treatment for congestive heart failure

CT-011 completes phase I study in advanced hematological malignancies

Intercell and Biological E sign Asia agreement for Japanese encephalitis vaccine

FDA clears phase I study of systemic administered Reolysin

AustCancer submits DMF for GPI-0100

Innovate Oncology acquires rights to Capridine-Beta for prostate cancer

BAL-5788 enters hospital-acquired pneumonia phase III trials

Fosamax Plus D receives FDA approval

Celgene completes Revlimid NDA submission for MDS

Eisai and Abbott to develop adalimumab for psoriasis in Japan

Bausch & Lomb discloses new therapeutic agents for ophthalmic diseases

Retisert receives FDA approval

New patents cover treatments for pain and inflammation

New data on the antiviral efficacy and the PK of celgosivir

Long-term effects of transdermal rotigotine in patients with early PD

A new study confirms the benefits of eszopiclone in chronic insomnia

Lasofoxifene induces no adverse effects on mood and cognition in postmenopausal women

Japanese manufacturing approval for tocilizumab for Castleman's disease

Japanese manufacturing approval for Lulicon

Promising results from in vitro and in vivo testing of human rhinovirus inhibitor

Prana will not advance PBT-1 into PLACQUE study

Long-acting naltrexone reduces heavy drinking in alcohol-dependent subjects

Phase III results on lucinactant in premature infants at risk for RDS

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...